6th Annual Summit on Controlled Substances - DS

EARN CLE CREDITS

March 14–15, 2023 | Washington, DC 6th Annual Summit on

CONTROLLED SUBSTANCES REGULATION, LITIGATION, AND ENFORCEMENT

Reconnect in-person with industry peers, key industry stakeholders from the controlled substances supply chain, and government officials, including leaders from DEA, DOJ and FDA, as we examine the latest regulatory and legal developments and trends impacting these products.

Distinguished Co-Chairs: Jolie Apicella Partner Wiggin & Dana LLP Gustav Eyler Partner Gibson, Dunn, & Crutcher LLP Cori Rizman Director, Compliance – Controlled Substances Oversight Region North America Fresenius-Kabi USA Former Diversion Investigator/Supervisor, DEA

SUPPORTING SPONSOR:

Exclusive Keynotes from DOJ, and FDA: Amanda Liskamm Director, Consumer Protection Branch U.S. Department of Justice

Dominic Chiapperino, Ph.D. Director, Controlled Substance Staff Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Industry thought leaders will help you: ĉ ASSESS the current status of the National Opioid Litigation and MDL Settlements ĉ ANALYZE the therapeutic potential of marijuana and psychedelics ĉ EVALUATE the role of Telemedicine in controlled substances prescribing, distribution, and abuse ĉ DEVELOP a comprehensive Controlled Substances Compliance Program ĉ RESPOND effectively to DEA and FDA investigations ASSOCIATE SPONSOR:

REGISTER NOW AmericanConference.com/ControlledSubstances • 888 224 2480

SPONSOR:

Part of C5 Group’s LIFE SCIENCES GLOBAL SERIES

American Conference Institute invites you to join our 6th Annual Summit on Controlled Substances: Regulation, Litigation, and Enforcement Over the past year, opioid-related enforcement remained a top federal and state priority, as seen through the record recoveries under the False Claims Act and the multi-district litigation against major manufacturers, distributors and pharmacies. Opioid-related enforcement continues to be a top government priority, especially due to the correlated increase in overdoses from the use of counterfeit pills that contain fentanyl.

However, opioids are not the only controlled substance on the governments’ radar: the increased use of telemedicine for the prescription of controlled substances during the COVID-19 pandemic has influenced a surge in prescriptions for amphetamines, such as Adderall, for the treatment of ADHD. Futhermore, in October 2022, the Biden Administration announced that it would begin pardoning all prior offences of simple possession of marijuana and asked that DEA and FDA begin the administrative process to review how marijuana is scheduled under federal law. In the near future, we may see new therapeutics involving THC, and lessons can be learned from the existing hemp, recreational, and medical marijuana industries. Equally, the pharmaceutical industry is on the cusp of an emerging paradigm in therapeutics: psychedelics. Impressive breakthroughs in clinical trials frequently make headlines as states continue to legalize the use of psychedelics.

The world of controlled substances enforcement, regulation and litigation is evolving, and the benefits of innovation must be carefully balanced against the risks and costs of non-compliance.

Who Should Attend?

• Compliance officers • Chief quality officers • Presidents/CEOs • Senior internal auditors • Directors of compliance • Regulatory/risk officers • Government employees • Pharmacists • General counsel • Compliance, regulatory and litigation attorneys

This March, connect with government officials and key industry stakeholders from throughout the controlled substances supply chain to examine the latest legal and regulatory developments impacting the industry. Attend and learn how to best conform business practices to meet growing regulatory demands, bolster compliance programs, mitigate risk, and reduce liability. Be part of the only conference that presents strategies and solutions for every link of the controlled substances supply chain.

Register Today

EARN CLE CREDITS

Continuing Legal Education Credits Accreditation will be sought in those jurisdictions requested by the registrants which have continuing education requirements. This course is identified as nontransitional for the purposes of CLE accreditation.

ACI certifies this activity has been approved for CLE credit by the New York State Continuing Legal Education Board.

ACI certifies this activity has been approved for CLE credit by the State Bar of California.

ACI has a dedicated team which processes requests for state approval. Please note that event accreditation varies by state and ACI will make every effort to process your request.

Questions about CLE credits for your state? Visit our online CLE Help Center at www.americanconference.com/accreditation/cle/

2 | #ControlledSubstances twitter: @ACI_Conferences linkedin: ACI: Pharmaceutical Groups

Distinguished Faculty Co-Chairs Jolie Apicella Partner Wiggin & Dana LLP Former AUSA, Chief of Healthcare Fraud, Eastern District of New York

Gustav Eyler Partner Gibson, Dunn, & Crutcher LLP Former Director of Consumer Protection Branch, U.S. Department of Justice

Government Dominic Chiapperino, Ph.D. Director, Controlled Substance Staff Center for Drug Evaluation and Research U.S. Food and Drug Administration Scott B. Dahlquist Opioid Coordinator, Consumer Protection Branch U.S. Department of Justice Matthew Feeley Deputy Chief & Healthcare Fraud Coordinator, USAO SDFL Civil Division U.S. Department of Justice

Francis Godwin Director, Office of Manufacturing Quality U.S. Food and Drug Administration Monica Hanna Special Counsel Office of the NY State Attorney General Jonathan Lenzner Chief of Staff Federal Bureau of Investigations Amanda Liskamm Director, Consumer Protection Branch U.S. Department of Justice

Lisa Miller Deputy Assistant Attorney General | Fraud and Appellate Sections U.S. Department of Justice, Criminal Division Anthony J. Nardozzi Assistant Director U.S. Department of Justice, Consumer Protection Branch, Civil Division Arun Rao Deputy Assistant Attorney General U.S. Department of Justice, Civil Division

Cori Rizman Director, Compliance – Controlled Substances Oversight Region North America Fresenius-Kabi USA Former Diversion Investigator/ Supervisor, DEA Gabriel H. Scannapieco Assistant Director, Consumer Protection Branch U.S. Department of Justice Elliot Schachner Assistant U.S. Attorney, Eastern District of New York U.S. Department of Justice Natalie Waites Assistant Director, Fraud Section, Civil Division U.S. Department of Justice Justin G. Wood Diversion Program Manager, Washington Division Drug Enforcement Administration

Industry Executives William Chang Chief Legal Officer, Corporate Secretary UpStream Healthcare Janet Hart Director, Government Affairs Rite Aid

Charles Graybow Senior Compliance Counsel Pfizer Cory Kopitzke Assistant General Counsel, Regulatory Cardinal Health Sarah Pechnick Senior Director Guidepost Solutions

Law Firm Attorneys Nathan A. Beaver Partner Foley & Lardner LLP Joseph J. Bogdan Founding Lawyer The Law Offices of Joseph J. Bogdan, LLC Ronald Chapman President Chapman Consulting Group Kimberly I. Chew Partner Husch Blackwell LLP

Todd Prough, Ph.D Controlled Substance Monitoring Program AmerisourceBergen Former Head of Pharmaceutical Investigations, DEA Julie Rapoport Schenker, Esq. Senior Counsel, Business and Litigation | Office of the General Counsel University of Maryland Medical System

Jayne Conroy Shareholder Simmons Hanly Conroy LLP

Jay Dewald Partner | Head of Healthcare Investigations Norton Rose Fulbright US LLP

Ethan Davis Partner King & Spalding LLP

Uttam Dhillon Partner | Chair, Regulatory Defense, Compliance & White Collar Practice Group Michael Best & Friedrich LLP

Hunter G. DeKoninck Attorney Quarles & Brady LLP Delia Ann Deschaine Partner Epstein Becker Green LLP

Jonathan Havens Partner | Cannabis Law Practice Co-Chair Saul Ewing LLP

Christine Roussel, PharmD, BCOP, BCSCP Senior Executive Director, Pharmacy, Laboratory and Medical Research Doylestown Health Member of the Pennsylvania Board of Pharmacy and Medical Marijuana Advisory Board Dr. Berra Yazar-Klosinski Chief Scientific Officer MAPS Public Benefit Corporation

Matthew J McCarthy Special Counsel Duane Morris LLP Jonathan M. Phillips Partner Gibson, Dunn & Crutcher LLP Lowell Zeta Partner Hogan Lovells US LLP Matthew C. Zorn Partner Yetter Coleman LLP

Marian J. Lee Partner Gibson, Dunn & Crutcher LLP

REGISTER NOW AmericanConference.com/ControlledSubstances • 888 224 2480

Part of C5 Group’s LIFE SCIENCES GLOBAL SERIES

Conference

DAY ONE

Tuesday, March 14, 2023

8:00 AM Registration and Breakfast 9:00 AM

Opening Remarks from the Co-Chairs Microphone Jolie Apicella, Partner, Wiggin & Dana LLP

Former AUSA, Chief of Healthcare Fraud, Eastern District of New York Gustav Eyler, Partner, Gibson, Dunn, & Crutcher LLP Former Director of Consumer Protection Branch, U.S. Department of Justice Cori Rizman, Director, Compliance – Controlled Substances Oversight Region North America, Fresenius-Kabi USA Former Diversion Investigator/Supervisor, DEA

9:15 AM

Fireside Chat with the DOJ Microphone Arun Rao, Deputy Assistant Attorney General,

Much of the $26 billion opioid settlement agreement announced in early 2022 will be used to fund state and subdivision initiatives for abatement of the opioid epidemic. However, not all the lawsuits are settled. In this session, topics of discussion include: • Lessons learned from the settled lawsuits and mitigation strategies for every link in the supply chain » Evaluating the arguments concerning unlawful advertising and promotion of the consequences for manufacturers » Identifying the arguments surrounding diversion and the consequences for distributors and pharmacies • Update on the $26 billion settlement agreement » What are the abatement initiatives and how will they be implemented • Reviewing the lawsuits that have not settled and comparing the different legal arguments

U.S. Department of Justice, Civil Division

» Analyzing the findings of the Johnson & Johnson Oklahoma trial and the implications for multidistrict litigation

Anthony J. Nardozzi, Assistant Director, U.S. Department of Justice, Consumer Protection Branch, Civil Division

» Making the strategic decision between judge-alone or jury trials

Lisa Miller, Deputy Assistant Attorney General | Fraud and Appellate Sections, U.S. Department of Justice, Criminal Division 9:45 AM

Reevaluating Controlled Substances Prescribing via Telehealth and Appreciating the Impact of the Expiring PHE Microphone William Chang, Chief Legal Officer, Corporate Secretary, UpStream Healthcare

Julie Rapoport Schenker, Esq., Senior Counsel, Business and Litigation | Office of the General Counsel, University of Maryland Medical System Nathan A. Beaver, Partner, Foley & Lardner LLP Scott B. Dahlquist, Opioid Coordinator, Consumer Protection Branch, U.S. Department of Justice • Considering the impact of the May 11, 2023, expiration of the PHE on controlled substances prescribing

11:45 AM

DOJ Keynote: Recent DOJ Civil and Criminal Enforcements Microphone Amanda Liskamm, Director, Consumer Protection Branch, U.S. Department of Justice

12:15 PM Networking Lunch 1:15 PM

Responding to Emerging Enforcement Trends – Counterfeit Pills, Precursors, and Amphetamines Microphone Ethan Davis, Partner, King & Spalding LLP Jonathan Lenzner, Chief of Staff, Federal Bureau of Investigation

» Will DEA create an official license for the prescribing of controlled substances via telehealth?

Uttam Dhillon, Partner | Chair, Regulatory Defense, Compliance & White Collar Practice Group, Michael Best & Friedrich LLP

» Operating safely during the interim period of the expired PHE and the implementation of new DEA registrants for telehealth prescribers

Gabriel H. Scannapieco, Assistant Director, Consumer Protection Branch, United States Department of Justice

• Detailing how the supply chain can prepare now for government’s plans to increase enforcement of telehealth prescribing » Best practices for operating with differing state and federal requirements 10:45 AM Networking Break 11:00 AM

National Opioid Litigation and MDL Settlement Update: Tracking Settlements, Agreements, and the Role of State Attorney Generals Microphone Monica Hanna, Special Counsel, Office of the New York State Attorney General

Moderator: Gustav Eyler, Partner, Gibson, Dunn, & Crutcher LLP, Conference Co-Chair • Update on expanded efforts to interdict counterfeit pills • Examining investigative and enforcement approaches aimed at stopping necessary precursor chemicals and equipment from reaching illegal drug manufacturers • Developing corporate engagement protocols to improve responsible sales, distribution, and reporting • Enforcement tools, approaches, and considerations related to amphetamine manufacturing, distribution, and dispensing • Compliance advice for corporate actors associated with or transacting in relevant chemicals, equipment, or drugs

Jayne Conroy, Shareholder, Simmons Hanly Conroy LLP

4 | #ControlledSubstances twitter: @ACI_Conferences linkedin: ACI: Pharmaceutical Groups

2:15 PM

Supply Chain Due Diligence for Manufacturers and Distributors: A Deep Dive into Satisfying DEA Diversion Obligations and Streamlining Suspicious Order Monitoring Microphone Hunter G. DeKoninck, Partner, Quarles & Brady LLP

Elliot Schachner, Assistant U.S. Attorney, Eastern District of New York, U.S. Department of Justice • Lessons learned from recent pharmacy chain rulings regarding diversion and how to not let this happen to your business • Developing best practices for communicating with prescribers when the necessity of the prescription is in question » Protocols for following up with prescriber red flags

Cory Kopitzke, Assistant General Counsel, Regulatory, Cardinal Health

» Knowing which red flags to report

Todd Prough, Ph.D., Controlled Substance Monitoring Program, AmerisourceBergen, Former Head of Pharmaceutical Investigations, DEA

• Analyzing guidelines and factors for determining the likelihood of diversion from the patient » Utilizing the Prescription Drug Monitoring Program as a tool » Going beyond reporting: can pharmacists refuse to fill prescriptions?

Sarah Pechnick, Senior Director, Guidepost Solutions • Unpacking Suspicious Order Monitoring (SOMS) parameters: » What exactly constitutes a “suspicious order” (SO) and a “order received under suspicious circumstances” (ORUSC) and what does that mean in practical terms for distributors • Learning how to design and operate a system to identify SOs and ORUSCs » What information must you include when you report a suspicious order or ORUSC to DEA? • Understanding the benefits of an ERP system and knowing the legal and compliance aspects of utilizing technology to fulfill diversion obligations • Training employees to comply with SOMS requirements

• Incorporating the Model State Pharmacy Act and Model Rules of National Association of Boards of Pharmacy (Model Act) and the PhRMA Code 4:45 PM

Ruan v. United States: What Prescribers and Their Lawyers Need to Know Microphone Jay Dewald, Partner | Head of Healthcare Investigations, Norton Rose Fulbright US LLP

Ronald Chapman, President, Chapman Consulting Group

• Best practices for conducting virtual and onsite visits with prospective customers » Knowing where to search for relevant information and knowing the right questions to ask » Identifying the common and lesser-known red flags according to industry practice, legislative guidance and case law » Considering the unique due diligence for international supply chains

In July of 2021, the Supreme Court in Ruan v the United States ruled that the Government must prove the defendant knowingly or intentionally acted in an unauthorized manner to find them guilty of unauthorized distribution of controlled substances. One year later, authorized prescribers need to know how this standard is being applied in practice to adopt their behaviors accordingly. In this session, topics of discussion include: • Understanding the guidance released by HHS following the Ruan and Khan cases

3:30 PM Networking Break

• Adapting prescribing practices and procedures based on the outcome

3:45 PM

• How is Ruan informing DOJ charging decisions, and what that means for your compliance program moving forward

PHARMACIST SPOTLIGHT

What Every Pharmacist and Non-Pharmacist Needs to Know About Proper Administration and Diversion of Prescribed Controlled Substances

5:45 PM

Day One Adjourns

Microphone Janet Hart, Director, Government Affairs, Rite Aid

Venue Information American Conference Institute is pleased to offer a variety of hotel suggestions near the DC Bar Association.

Hotel:

Hampton Inn Washington-Downtown Convention Center

Hotel:

Homewood Suites by Hilton Washington DC Convention Center

Address:

901 6th St NW, Washington DC 20001

Address:

465 New York Ave NW, Washington DC 20001

Reservations: (202) 842-2500

Reservations: (202) 628-4663

In-Person Conference Participation Requirements

The D.C. Bar Associations has the following requirements in place to be considered “Fully Vaccinated”.

Please note that the D.C. Bar Association facility currently has COVID-19 vaccination requirements in place for all visitors.

All visitors to the facility must be “Fully Vaccinated“ - or - non-vaccinated individuals will require proof of a negative COVID-19 test from a healthcare provider or testing facility. At-home or self-administered test results will not be accepted. Negative test results must be accompanied with a government-issued ID. Upon arrival, you will be required to present your CDC COVID-19 Vaccination Record Card, or a similar record for visitors who are residents of countries other than the U.S., to security personnel located in the building lobby. Vaccination proof or negative test results must be accompanied with a government-issued ID. While on-site, individuals are not required to wear face masks but are encouraged to do so and practice social distancing.

U.S. Residents: Visitors must have received two (2) doses of the Pfizer-BioNTech or Moderna vaccine, OR a single dose of the Johnson & Johnson/Janssen vaccine; AND Visitors must have received at least one booster shot in accordance with the current CDC guidelines.

International Visitors: Visitors must have received doses of the COVID-19 vaccines listed below in any combination in accordance with current World Health Organization (WHO) guidelines.

AstraZeneca/Oxford Pfizer/BionTech Covovax vaccine Sinopharm Nuvaxovid Johnson and Johnson Sinovac CanSino Moderna COVAXIN

REGISTER NOW AmericanConference.com/ControlledSubstances • 888 224 2480

Part of C5 Group’s LIFE SCIENCES GLOBAL SERIES

Conference

DAY TWO

Wednesday, March 15, 2023

8:00 AM Registration and Breakfast

11:00 AM

Opening Remarks from the Co-Chairs

Taking the Bad Trip Out of Psychedelic Medicines: Investing in An Emerging New Paradigm in Therapeutics

Microphone Jolie Apicella, Partner, Wiggin & Dana LLP

Microphone Kimberly I. Chew, Partner | Co-founder and Co- Lead of Psychedelic and

9:00 AM

Former AUSA, Chief of Healthcare Fraud, Eastern District of New York

Gustav Eyler, Partner, Gibson, Dunn, & Crutcher LLP Former Director of Consumer Protection Branch, U.S. Department of Justice Cori Rizman, Director, Compliance – Controlled Substances Oversight Region North America, Fresenius-Kabi USA Former Diversion Investigator/Supervisor, DEA 9:15 AM

Emerging Therapies Practice Group, Husch Blackwell LLP Dr. Berra Yazar-Klosinski, Chief Scientific Officer, MAPS Public Benefit Corporation

Psychedelics are increasingly making headlines, especially for the treatment of mental illnesses such as PTSD. Exciting new drug applications involving MDMA, DMT, and psilocybin are making their way through clinical trials and the political and public policy cadence continues to shift towards recognizing the medical value of psychedelics; the DEA is also looking to dramatically boost the production quotas of certain psychedelics, including LSD, psilocyn and mescaline.

Keynote: FDA Enforcement Priorities

• Which psychedelics are closest to FDA approval and which remain on the fringes?

Microphone Dominic Chiapperino, Ph.D., Director, Controlled Substance Staff,

• Navigating the difficulty of securing psychedelics for research in order to demonstrate its medical value

Center for Drug Evaluation and Research, U.S. Food and Drug Administration

» Best practices for applying for a DEA research license » Partnering with universities and research institutions

9:45 AM

Scheduling and Rescheduling Controlled Substances Microphone Matthew C. Zorn, Partner, Yetter Coleman LLP Delia Ann Deschaine, Partner, Epstein Becker Green • Reviewing the legal pathways to scheduling and rescheduling: administrative and legislative » Assessing the credibility and reliability of the data and evidence used in the scheduling process SQUARE

Strategies for demonstrating a drug has little or no potential for abuse

• Historical review of drugs that have been scheduled legislatively (e.g., gamma-hydroxybutyric acid, a date rape drug) • Understanding how and when public petitions for administrative scheduling occur (e.g., the 2002 rescheduling of buprenorphine) • An update on the challenge to DEA’s rescheduling petition denial (Right to Try) in the U.S. Court of Appeal’s 9th circuit • Considering international treaties in the context of rescheduling 10:45 AM Networking Break

• Best practices for comprehensive IND and NDA applications • Reviewing the other pathways including Special Protocol Assessment, Breakthrough Therapies, Fast Track and Priority Review 12:00 PM

Breaking Into the Cannabis Market: Balancing the Profits Against the Risks of Non-Compliance Microphone Jonathan Havens, Partner | Cannabis Law Practice Co-Chair, Saul Ewing LLP

Christine Roussel, PharmD, BCOP, BCSCP, Senior Executive Director, Pharmacy, Laboratory and Medical Research, Doylestown Health Member of the Pennsylvania Board of Pharmacy and Medical Marijuana Advisory Board Matthew J McCarthy, Special Counsel, Duane Morris LLP In October 2022, the Biden Administration announced that it would begin pardoning all prior offences of simple possession of marijuana and asked that DEA and FDA begin the administrative process to review how marijuana is scheduled under federal law. DEA has also proposed to more than double the amount of cannabis that can be legally manufactured for research in 2023. The implications of rescheduling marijuana are massive, and may transform the cannabis market into one that is legal at the federal as well as state level. In this session, topics of discussion include: • Reviewing DEA and FDA stances on Delta 8 THC » Are designer compounds worth the risk of attracting DEA or FDA interest?

Envelope

Join Our Email List to Stay Connected.

• Drawing on the experiences of pre-existing companies within the hemp and medicinal marijuana industries to set their business up as FDA and DEA compliant

AmericanConference.com/join-our-email-list/

• Developing business solutions for the inability of state companies to use federal banks and federal tax deductions

Sign up to receive exclusive discounts, offers and program updates.

• Understanding how hemp products can and cannot be marketed

6 | #ControlledSubstances twitter: @ACI_Conferences linkedin: ACI: Pharmaceutical Groups

1:00 PM Networking Lunch 2:15 PM

Ensuring cGMP Compliance and Quality Standards for Controlled Substances Microphone Francis Godwin, Director, Office of Manufacturing Quality, U.S. Food and Drug Administration

Marian J. Lee, Partner, Gibson, Dunn & Crutcher LLP Lowell Zeta, Partner, Hogan Lovells US LLP • Reviewing current Good Manufacturing Practice regulations relative to controlled substances » Ensuring product integrity through product and facility registration; inspections; chain-of-custody documentation; and technologies to protect against counterfeit, diverted, subpotent, adulterated, misbranded, and expired drugs.

• Knowing the standards for active pharmaceutical ingredients » Learning the unique considerations for contract manufacturing • Reviewing the current Chemistry, Manufacturing and Controls regulations » Synchronizing CMC and GMP » Considering the draft Quality System Regulation and OMB’s review 3:15 PM Networking Break 3:30 PM

Managing the Finer Points of Parallel Investigations: Reconciling the Requirements of the False Claims Act and the Controlled Substances Act Microphone Matthew Feeley, Deputy Chief & Healthcare Fraud Coordinator, USAO SDFL Civil Division, U.S. Department of Justice

Natalie Waites, Assistant Director, Fraud Section, Civil Division, U.S. Department of Justice Jonathan M. Phillips, Partner, Gibson, Dunn & Crutcher LLP Charles Graybow, Senior Compliance Counsel, Pfizer Moderator: Jolie Apicella, Partner, Wiggin & Dana LLP Former AUSA, Chief of Healthcare Fraud, Eastern District of New York Conference Co-Chair Parallel investigations have unique considerations that must be considered when developing your legal, compliance and business strategies Enforcement trends show that federal authorities target individual actors for criminal sanctions under the Controlled Substances Act, and target corporate entities for civil remedies, frequently under both the False Claims

hands-helping BECOME A SPONSOR With conferences in the United States, Europe, Asia Pacific, and Latin America, the C5 Group of Companies: American Conference Institute, The Canadian Institute, and C5 Group, provides a diverse portfolio of conferences, events and roundtables devoted to providing business intelligence to senior decision makers responding to challenges around the world.

Don’t miss the opportunity to maximize participation or showcase your organization’s services and talent. For more information please contact us at: SponsorInfo@AmericanConference.com

Act and the Controlled Substances Act. Parallel investigations have unique considerations that must be considered when developing your legal strategy. In this session, topics of discussion include: • Reviewing the CSA civil penalty and FCA framework to understand what actions may give rise to a claim under the Act; » Understanding CSA civil provisions » Learning the anatomy of an FCA lawsuit • Implementing effective and comprehensive FCA compliance measures and outlining best practices to maintain FCA compliance • Distinguishing between corporate and individual liability and knowing which factors can negatively or positively affect the other » When is it in the corporation’s interest to self-disclose and cooperate with investigations into individual actors within the corporation? » What are the privacy and self-incrimination considerations? » Understanding the new Monaco memo requirements • Knowing when to hire outside counsel to avoid conflicts of interest 4:30 PM

Responding Effectively to DEA Investigations: Tailoring Inspection Strategies for Every Link in the Supply Chain Microphone Joseph J. Bogdan, Founding Lawyer, The Law Offices of Joseph J. Bogdan, LLC

Justin Wood, Diversion Program Manager, Drug Enforcement Administration Moderator: Cori Rizman, Director, Compliance – Controlled Substances Oversight Region North America, Fresenius-Kabi USA Former Diversion Investigator/Supervisor, DEA • Responding to Letters of Admonition within the allotted time frame • Understanding when to participate in Informal Administrative hearings with DEA » Knowing when self-disclosure goes too far » Negotiating suitable terms for a Memorandum of Understanding • Preparing for an Order to Show Cause » Learning the legal argument trends that do and do not result in license revocation » Dealing with license revocation • Working within the confines of an Immediate Suspension Order 5:30 PM

Conference Concludes

About us:

The C5 Group, comprising American Conference Institute, The Canadian Institute and C5 in Europe, is a leading global events and business intelligence company.

For over 35 years, C5 Group has proVided the opportunities that bring together business leaders, professionals and international experts from around the world to learn, meet, network and make the contacts that create the opportunities.

Our conferences and related products connect the power of people with the power of information, a powerful combination for business growth and success.

REGISTER NOW AmericanConference.com/ControlledSubstances • 888 224 2480

Part of C5 Group’s LIFE SCIENCES GLOBAL SERIES

American Conference Institute’s 40 th

UPCOMING EVENTS

Women Leaders LIFE SCIENCES LAW 9TH ANNUAL SUMMIT FOR

DRUG&MEDICAL DEVICE L I T I G AT I O N

IN

December 6–7, 2022

March 22–23, 2023

New York, NY

WORRY FREE Registration

July 26–27, 2023

Virtual

Boston, MA

Book with confidence!

Register and pay to lock in your early rate and be eligible for a full refund until February 27.

If you are unable to attend for any reason, you will have the following options:

GUARANTEE

y A full credit note for you, or a colleague to attend another event. y A full refund.

All cancellations and changes must be submitted to customerservice@americanconference.com by February 27.

Can’t Attend In-Person?

Attend the livestream from the comfort of your home or office.

image of event website

Emma McAdam VP, Government Affairs

Janet Smith VP, General Counsel

Immerse yourself in live presentations, panel discussions, specialized breakout sessions and networking opportunities.

Engage in meaningful dialogue with attendees and speakers in an interactive format.

Looking to Register?

Contact our Customer Service Representatives:

Meet 1-on-1 with attendees you select and exchange contact information for lasting connections and true engagement.

Olivia Thomson Chief Compliance Officer

Luis Santos Director

Ramesh Kumar Partner

Amanda Liskamm Director, Consumer Protection Branch U.S. Department of Justice

Expand your network to a global audience.

Eric Triana Deputy Assistant Administration, Diversion Control Division Drug Enforcement Agency (DEA)

Patricia Harden Head of Sanctions

Monica Hanna Special Counsel Office of the NY State Attorney General

Miyuki Johnson VP, Manufacturing

Matthew Feeley Deputy Chief & Healthcare Fraud Coordinator, USAO SDFL Civil Division U.S. Department of Justice

Visit solution providers and learn about the latest technologies, services and products.

Yanette Ching American Conference Institute

Dan Manganiello American Conference Institute



Y.Ching@AmericanConference.com



D.Manganiello@AmericanConference.com



1 212 352 3220 x5499



1 212 352 3220 x5464

Use Registration Code: B00-999-YCG23

Register & Pay by January 6, 2023

PRICING

Jean Roux VP, Business Development

Government Insights from:

Use Registration Code: B00-999-DMO23

Register & Pay by February 10, 2023

Register & Pay after February 10, 2023

$2195

$2395

CONFERENCE CODE:

750L23-WAS

IN-PERSON Conference

$2095 LIVESTREAM

Conference

$1895

$1995

$2195

All program participants will receive an online link to access the conference materials as part of their registration fee.

Additional copies of the Conference Materials available for $199 per copy.

To update your contact information and preferences, please visit https://www.AmericanConference.com/preference-center/.

Terms & conditions and refund/cancellation policies can be found at AmericanConference.com/company/faq/

PLEASE NOTE THE FOLLOWING PANDEMIC-RELATED PROTOCOLS: ACI conferences and events will be organized in accordance with the latest health and safety regulations, guidelines, and recommendations, directed by the CDC and local government authorities. Attendees are advised to consider their personal health needs.

© American Conference Institute, 2023

Attendees are asked to self-screen in the days leading up to, before and after attending an ACI event and/or conference.

We will continue to monitor the health situation and relevant authorities. Changes to health and safety measures may be made by ACI at any time as required.

Bringing a Team?* 3–4

10% Conference Discount

5–6

15% Conference Discount

7

20% Conference Discount

8+

Call 877-927-7936

Special Discount ACI offers financial scholarships for government employees, judges, law students, non-profit entities and others. For more information, please email or call customer service. * Team/group registrations must be from the same organization/firm and register together in one transaction.